

DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Metabolic and Endocrine correlates of cognitive function in healthy young women

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation	Bove, R.M., D.J. Brick, B.C. Healy, S.M. Mancuso, A.V. Gerweck, M.A. Bredella, J.C. Sherman, and K.K. Miller. 2012. "Metabolic and Endocrine correlates of cognitive function in healthy young women." Obesity (Silver Spring, Md.) 21 (7): 1343- 1349. doi:10.1002/oby.20212. http://dx.doi.org/10.1002/oby.20212.
Published Version	doi:10.1002/oby.20212
Accessed	February 19, 2015 3:16:55 PM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879658
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)



NIH Public Access

Author Manuscript

Obesity (Silver Spring). Author manuscript; available in PMC 2014 January 01

Published in final edited form as:

Obesity (Silver Spring). 2013 July ; 21(7): 1343–1349. doi:10.1002/oby.20212.

Metabolic and Endocrine correlates of cognitive function in healthy young women

R.M. Bove¹, D.J. Brick², B.C. Healy³, S.M. Mancuso⁴, A.V. Gerweck², M.A. Bredella⁵, J.C. Sherman⁴, and K.K. Miller²

¹Department of Neurology, Brigham and Women's Hospital and Harvard Medical School

²Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School

³Massachusetts General Hospital Biostatistics Center, Boston, MA 02114

⁴Psychology Assessment Center, Massachusetts General Hospital and Harvard Medical School

⁵Department of Radiology, Massachusetts General Hospital and Harvard Medical School

Abstract

Obesity has been associated with cognitive decline in longitudinal studies of older individuals. We hypothesized that the cognitive sequelae of obesity may be detectable in the reproductive years. In addition, we explored the hypothesis that these associations may be mediated by the hormonal milieu.

In this study of 49 young healthy lean and overweight women aged 20–45, we investigated the association between performance on a battery of cognitive tests, body composition parameters (BMI, total fat, abdominal (visceral, subcutaneous and total) adipose tissue, and muscle), and hormone levels (insulin, adiponectin, leptin, IGF-1, estrogen, testosterone, and vitamin D). We found a significant negative association between both visceral adiposity and muscle, and performance in the domain of verbal learning and memory, after controlling for age and education. Other body composition parameters showed similar trends (0.05). Additionally, the degree of insulin resistance was negatively associated with executive function domain. None of the associations between the other hormones examined (adipokines, IGF-1, gonadal hormones and vitamin D) and cognitive function were significant.

These preliminary findings suggest a possible association between obesity and cognitive function in healthy young women of reproductive age. More research is warranted into the potential modulatory effect of insulin resistance on this association.

Introduction

Obesity is a growing epidemic in the United States, with considerable impact on health care expenditures, morbidity and mortality¹. Over the past decade, obesity has been increasingly associated with cognitive decline, particularly in older individuals. In cross-sectional studies, elevated body mass index (BMI, kg/m²), as well as the metabolic syndrome, have been associated with deficits in memory, executive function, processing speed, semantic fluency, and overall cognitive function^{2–4}. Detailed longitudinal studies have shown that elevated

Disclosures

Correspondence: Riley Bove, M.D., Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, Fax: (617) 525-5333, Telephone: (617) 525-5330, rbove@partners.org.

None of the manuscript authors have any conflicts of interest relative to this manuscript to declare.

BMI is an independent risk factor for accelerated brain atrophy, and increased risk of cognitive decline, including Alzheimer's disease ^{5–7}.

In younger individuals, deficits in attention, executive function, verbal learning, verbal memory and manual coordination have been noted with increasing BMI^{8–14}. However, most of these studies have focused either on adolescents¹⁴ or middle-aged adults (e.g. mean age 49¹³), describe patients specifically presenting for treatment of their obesity ^{9,12}, and use limited measures of either cognitive outcome (e.g. executive function ¹⁰) or body composition (e.g. BMI or waist-hip ratio ¹³).

The association between obesity and cognitive impairment may not result solely from such known risk factors as dyslipidemia, hypertension, and endothelial dysfunction¹³. Recent evidence suggests that the hormonal milieu associated with obesity may itself modulate cognitive changes. Insulin resistance has been most frequently proposed as a regulator of this process, likely because of the link between metabolic syndrome and cognitive dysfunction^{15,16}. Cognitive domains implicated include executive function ², verbal fluency¹⁷ and working memory^{18, 19}. Similarly, the hormone insulin-like growth factor 1 (IGF-1) has been shown to exert neurophysiologic effects: it positively predicts cognitive development among children ²⁰, and may be neuroprotective against cognitive decline in the middle and later years ^{21–23}, but this has not been studied in premenopausal women. Studies of other hormones, including adiponectin^{2,24}, leptin²⁵, estrogen ²⁶, testosterone ^{27,28} and vitamin D²⁹ have shown more variable results, partially due to small sample sizes and variable study design.

To our knowledge, this study is the first to investigate in detail the association of cognitive function with weight and body composition in healthy 20–45 year old women, and to explore hormonal correlates of this effect. We obtained detailed measures of cognitive function, body composition variables, and hormonal profiles in overweight participants and normal-weight controls. Our first aim was to test the hypothesis that even in young healthy women, cognitive function is negatively associated with weight and body composition. Our second aim, based on the emerging evidence for endocrine mediation outlined above, was to explore associations between cognitive function and selected hormone levels.

Methods and Procedures

Subjects

Forty-nine eumenorrheic, healthy women were enrolled in the study. Thirty-seven of these women had BMI 25 kg/m² and waist circumference >88 cm, of whom 34 were a subset of a cohort of 76 women entered in a longitudinal study examining the effects of growth hormone replacement on abdominal obesity³⁰. Because the present study was initiated after the longitudinal one, only 34 of these women were enrolled, and they were enrolled consecutively. The remaining women (N=12) were of normal weight, with 18 < BMI < 25 kg/m². Subjects were recruited by advertisement. Inclusion criteria included age 20–45 years, BMI >18 kg/m², and a complete set of body composition parameters available at baseline. Exclusion criteria included English as a second language, color-blindness, smoking, pregnancy or breastfeeding, hypothalamic or pituitary disorders, diabetes mellitus or other chronic illnesses, estrogen or glucocorticoid use, use of statins or anti-hypertensives, and a score of moderate or major depression on the Beck Depression Inventory.

Protocol

The study was approved by the Partners Healthcare, Inc. Institutional Review Board, and written, informed consent was obtained prior to initiating any procedures. Each subject was

admitted to the Clinical Research Center at Massachusetts General Hospital for outpatient testing. Fasting serum was drawn for insulin, glucose, gonadal hormones and adipokines (see Biochemical Analysis), followed by a 75-g, 2-hour oral glucose tolerance test (OGTT) to measure glucose and insulin at 30, 60, 90 and 120 minutes after glucose load. Cross-sectional computed tomography (CT) and dual-energy x-ray absorptiometry (DXA) were performed to measure body composition.

A detailed battery of cognitive tests was then administered. All cognitive scoring was performed at the Massachusetts General Hospital Psychology Assessment Center. Initial questions included age, years of education, and handedness. Additionally, participants completed the Beck Depression Inventory (BDI), a 21-item self-report rating inventory measuring characteristic attitudes and symptoms of depression. Then, subjects underwent the following battery of standardized neuropsychological tests, which have been reviewed in detail ³¹:

- Wechsler Test of Adult Reading (WTAR): measures adult reading as an estimate of IQ
- Trail-Making Tests A and B:
 - A: test of visual attention and tracking
 - B: test of executive function requiring set shifting, alternately connecting letters and numbers
- California Verbal Learning Test, Second Edition (CVLT-II): test of verbal learning and memory
- Stroop test (D-KEFS version): test of selective attention, response inhibition and set shifting
- Rey Complex Figure (RCF): test of visual construction, organization and (nonverbal) memory
- Digit Symbol Substitution Test (DSS): test of executive function and processing speed
- Verbal Fluency (D-KEFS version): test of behavioral initiation, lexical access and set shifting

Biochemical Analyses

Serum samples were collected and stored at -80 °C. Serum total IGF-1 levels were measured using a solid-phase enzyme-labeled chemiluminescent immunometric assay on the Immulite 2000 automated immunoanalyzer (Siemens Medical Solutions Diagnostics, Los Angeles, CA) with an inter-assay coefficient of variation (cv) of 3.7-4.2%. Estradiol, glucose, insulin, and sex hormone binding globulin (SHBG) were measured by automated immunoassay (Architect; Abbott Diagnostics, Chicago, IL). The lower limit of detection of estradiol was 10 pg/ml, with an intra-assay cv of 1.4–6.4%. The lower limit of detection of insulin was 1.0 NU/ml, with an intra-assay cv of 1.9-5.2% and with an inter-assay cv of 2.0–9.6%. The lower limit of detection of SHBG was 0.01 nmol/l, with an intra-assay cv of 5.65–9.54%. Serum testosterone levels were measured by a solid-phase radioimmunoassay Coat-A-Count RIA kit (Siemens Medical Solutions Diagnostics, Los Angeles, CA) with a minimum detection limit of 2.2 pg/ml and an intra-assay cv of 0.5-1.9%. Free testosterone levels were calculated from total testosterone and SHBG using the laws of mass action³², and free estradiol levels were calculated from total estradiol and SHBG using the laws of mass action. Adiponectin (total and high molecular weight [HMW] forms) was measured by enzyme-linked immunosorbent assay (ALPCO Diagnostics, Inc., Salem, NH), with an intra-

assay cv of less than 8%, and an inter-assay of less than 10%. Leptin was measured using an ELISA kit (Millipore, Milwaukee, WI), with a sensitivity of 0.5 ng/ml, an intra-assay cv of 2.6–4.6%, and an inter-assay cv of 2.6–6.2%. Vitamin D was measured by an IDS-iSYS Multi-Discipline Automated Analyzer based on chemiluminescence technology (Immunodiagnostic Systems, Inc., Fountain Hills, AZ), with a minimum detection limit of 3.6 ng/ml and a within-run cv of 5.5 to 12.1%.

Body Composition Analysis

Body fat mass was determined with dual energy x-ray absorptiometry (DXA) using a Hologic QDR 4500 scanner (Hologic Inc., Waltham, MA). Adipose tissue and muscle areas were measured with a LightSpeed CT scanner (General Electric, Milwaukee, WI). Scan parameters: 144 cm table height, 80kV (abdomen), 120 kV (thigh), 70 mA (abdomen), 170 mA (thigh), 1 cm slice thickness, scan time 2 seconds, 48 cm FOV. Single-slice cross-sectional CT of the abdomen at the level of L4 was obtained to determine abdominal subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and total adipose tissue (TAT). Single-slice cross-sectional CT of the left mid-thigh was obtained to determine fat and muscle cross sectional areas (CSA). Analyses were performed using Alice software (version 4.3.9 Parexel, Waltham, MA).

Statistical Analysis

Data were analyzed using the SAS software program JMP, version 8.0.1 (Cary, N.C.). Raw cognitive test results were centered from the sample mean. Tests were then grouped into specific cognitive domains. Cognitive domain z scores for each subject were calculated by first summing the individual z scores for each of the test scores within the cognitive domain subscales and then subtracting each participant's score from the sample mean and dividing by the standard deviation of the sample.

The cognitive domains are as follows:

- 1. Processing Speed: DSS, Stroop Color, Stroop Word
- 2. Executive function: Verbal Fluency Letter, Verbal Fluency Category
- **3.** Verbal Learning and Memory: CVLT-II (Short Delay Free Recall; Short Delay Cued Recall; Long Delay Free Recall; Long Delay Cued Recall; Trials 1–5)
- 4. Visual Memory: RCF Immediate, RCF Delayed
- 5. Visuospatial skills: RCF Copy

Additional cognitive outcomes were not included because they did not add any unique explanatory power to the models.

Our primary analysis was to examine the association between BMI and other body composition parameters, and cognitive outcomes. Our secondary analysis was to explore the association between individual hormones and cognitive outcomes. Multivariate standard least squares regressions were constructed between each cognitive domain z-score and individual body composition (BMI, total adiposity (TAT), visceral adiposity (VAT), subcutaneous adiposity (SAT), total fat, and muscle CSA) and hormones ((1) glucose homeostasis, (2) IGF-1, (3) adipokines, (4) gonadal steroids, and (5) vitamin D), adjusting for age and education. It should be noted that because a limited number of subjects had adipokines drawn (adiponectin, N=30 and leptin, N=32), the N for these analyses was consequently reduced. For each body composition parameter, the association with cognitive scores was investigated both assuming a linear relationship and by categorizing the body composition parameter into three groups. For BMI, WHO criteria were used to categorize

patients into overweight and obese categories, and for other parameters tertiles were used to categorize subjects. If the three groups were significantly different by overall ANOVA, pairwise comparisons were performed. When a cognitive domain yielded a significant result, then individual tests within those domains were examined using the same approach.

In addition to these primary analyses, three additional analyses were investigated to better understand the combined relationship of body compositions measures and hormones. First, given the effect of menstrual cycle on cognitive functioning ³³, we completed all of the previous analyses also adjusting for estradiol. Second, to assess the independent effect of body composition measures on each cognitive measure with a significant association, the original models for the body composition were also fit controlling for BMI. Third, for hormones and body composition parameters revealing significant associations with cognitive outcomes, we then included each individual body composition parameter in turn, as well as each hormone, in the model to assess whether the body composition and endocrine effects were independent. Additional analyses of the combined effects and interactions among the hormones and body composition measures were not completed given our limited sample size.

Results

1. Subject characteristics (Table 1)

Subjects had a mean age of 35 years, a mean BMI of 31.5 kg/m², and had completed on average at least 4 years of college education. Ninety percent were right-handed. All subjects were normotensive. Overweight/obese women were on average older, less educated and with lower WTAR scores than normal weight women; however none of these differences was statistically significant.

2. Association between body composition parameters and cognitive function

In linear regression models with parameters treated as continuous variables, we found a significant negative association between both VAT and muscle and performance in the domain of verbal learning and memory, after controlling for age and education (Table 2). All other markers of body composition examined also showed trends toward negative associations with performance in this domain (0.05 . Of the individual tests examined, Trials 1–5 consistently revealed a statistically significant association with all body composition markers. In linear regression models with parameters treated as categorical, we found a significant negative association between SAT (p=0.010) and TAT (p=0.019) and verbal learning and memory, but not for muscle (p=0.114), BMI (p=0.087), VAT (p=0.143) or total fat (p=0.089). Figure 1 highlights these associations, with cognitive outcomes adjusted for age and education. The domains of executive function, processing speed, visuospatial skills and visual memory revealed no statistically significant associations with any body composition parameters (Supplementary Table 1).

3. Association between endocrine markers and cognitive function

There was a statistically significant negative association between HOMA-IR and executive function, in multivariate regressions performed for cognitive domains and individual hormones, adjusting for age and education (r=0.322, p = 0.021, Figure 2). When the individual tests of the executive domain were investigated, a statistically significant negative association with DKEFS category was observed (partial r=-0.301, p=0.042), but not with DKEFS letter (p=0.062). None of the other hormones examined revealed any significant associations with cognitive outcomes after controlling for age and education (Supplementary Table 2).

4. Combined effects of body composition and hormone levels on cognitive function

Given the associations above, several additional multivariate models were fit to investigate the combined effect of the measures. First, all models were run with estradiol as an additional predictor. The inclusion of estradiol did not change which body composition or endocrine variables were found to be significantly associated with cognitive outcomes.

Given the considerable correlations between individual body composition parameters (Supplementary Table 3), additional models were run with individual body composition parameters adjusting for age, education and BMI to identify which measures had an independent effect on verbal learning and memory. These revealed that neither BMI nor any of the fat/muscle parameters (total fat, total muscle, TAT, SAT, VAT) was significant at p<0.05 when both BMI and individual fat/muscle parameters were included in the model, possibly reflecting colinearity between these measures.

Finally, given the correlation between HOMA-IR and individual body composition parameters (Supplementary Table 3), two sets of additional models were run to examine significant findings from Sections 2 and 3 above. In the first, in order to assess whether HOMA-IR was independently associated with executive functioning when controlling for the individual body composition measures, we fit separate regression models in each case. When individual body composition markers were added into the model in turn, the association between HOMA-IR and executive function domain remained significant when controlling for muscle (p=0.022) and SAT (p=0.045), was suggestive for VAT, TAT and BMI (0.05), and was not significant for total fat (p=0.103). When total testosterone was added to the model including HOMA-IR, age and education, this measure showed a trend toward an effect.

In the second, in order to assess whether body composition measures remained significantly associated with cognitive performance after controlling for HOMA-IR, we fit separate regression models in each case. In regression models with parameters treated as continuous, controlling HOMA-IR as well as age and education, we continued to find a significant negative association between performance in the verbal learning and memory domain for VAT (p=0.0057) and muscle (p=0.009); the association was now also significant for TAT (p=0.023) and remained suggestive for BMI, SAT and total fat (0.05). When parameters were treated as categorical, VAT (p=0.041), muscle (p=0.0465) and TAT (p=0.0061) remained significant; SAT (p=0.0022) and total fat (p=0.0363) were now significant, and BMI remained suggestive (p=0.067). When we performed these analyses controlling for HOMA-IR for all other cognitive function domains, only VAT when treated as categorical but not as continuous, showed a significant association with performance in the visual memory domain (p=0.020 and p=0.275, respectively).

Discussion

The major finding of this study is that in young, healthy, highly educated women of reproductive age without comorbidities, body composition parameters associated with obesity are negatively correlated with cognitive function in the domain of verbal learning and memory. These findings may support an emerging body of literature linking obesity with cognitive dysfunction not only in the elderly, who have comorbidities (hypertension, hyperlipidemia, diabetes mellitus, cerebral microvascular disease), but also in the young¹⁰. In this study, we administered a comprehensive battery of cognitive tests. Our subject recruitment, from a healthy population of female volunteers aged 20–45, differs from other small detailed studies of cognitive function in the young, either in (1) age group, where mostly adolescents ¹⁴ or adults with mean age late 40s ¹³ have been described; (2) subject recruitment from a healthy volunteer population rather than a clinic for obesity

treatment ^{9,12}, or (3) more detailed measures were used than prior measures of either cognitive outcome (e.g. executive function¹⁰ or psychomotor speed¹¹) and body composition (e.g. BMI or waist-hip ratio¹³).

Additionally, we found a more significant association between detailed measurements of body composition (visceral adiposity and muscle) and relative deficits in cognitive function, than for BMI. These findings support the hypothesis that visceral adiposity may be a more important contributor to dementia than is BMI *per se*³⁴. Although in older adults muscle wasting is associated with cognitive decline³⁵, in our study of younger women, muscle cross-sectional area was negatively associated with cognitive function. This probably reflects the fact that our subjects with higher BMIs also had higher amounts of muscle in addition to higher amounts of fat, either from the increased thigh muscle required to support increased weight, or from fatty infiltration of muscle. Supporting this hypothesis, we found no associations between thigh muscle and verbal learning and memory when controlling for BMI. To our knowledge no other studies have examined the relationship between muscle and cognitive function in young healthy women, and these findings require replication and further investigation.

While it is possible that even in young adults, cognitive function is affected by silent cerebrovascular sequelae of obesity, hormonal correlates of cognitive function may be important modulators. Insulin resistance in particular has been studied ^{15–17,19} and may mediate cognitive function through modulation of hippocampal synaptic plasticity ³⁶, neuroinflammation and subsequent protein deposition ³⁷, and may have gender-specific effects due to interactions with gonadal steroids ³⁸. Insulin resistance has been implicated in cognitive dysfunction in neurologically normal older adults, even in the absence of silent microvascular disease on MRI². In this study, we found that HOMA-IR levels were negatively correlated with executive function. Interestingly, when we controlled for HOMA-IR, the association between body composition parameters and verbal learning and memory remained, and for some parameters even became, significant, suggesting that several mechanisms are at play. Additionally, while prior studies have shown that high levels of serum IGF-1 appear to be both predictive of cognitive development among children ²⁰ and protective against cognitive decline in the middle and later years²³, we did not detect any association in this study.

In this exploratory analysis of endocrine markers of cognitive function, we investigated whether the adipokines adiponectin, which is associated with insulin regulation and fatty acid metabolism, and leptin, a hormone signaling appetite, were associated with cognitive function, but detected no effect. Prior studies of adipokines and cognitive function, primarily in the elderly, have yielded conflicting results^{2,24,25,39}. The potential neuroprotective effects of vitamin D metabolism have generated considerable research interest, with potential positive effects of higher levels in the elderly²⁹, but not definitively in adults aged 20–59⁴⁰; in this study, no association was noted. Finally, there has been intense interest in the effect of sex hormones on cognition, especially with the decline in estrogen levels at menopause²⁶. Testosterone may also be neuroprotective, with middle levels of testosterone associated with best cognitive functioning in the elderly²⁷, but studies in younger subjects have not shown correlation between testosterone levels and cognitive tasks ²⁸. In this study of young individuals, gonadal hormones did not show any association with cognitive function independently of age and education.

There were two main study limitations. First, the cross-sectional nature of the data precluded inferring causality. Thus, we cannot ascertain whether relative cognitive dysfunction results in behaviors leading to weight gain, or whether obesity causes relative cognitive dysfunction. Second, there were small numbers overall in this exploratory study. We were

likely underpowered to identify specific endocrine associations, albeit small, which in a larger sample, might be statistically significant after controlling for age and education. Effect sizes are provided in Supplementary Table 3 in order to facilitate power calculations for future studies. Further, our limited sample size precluded us from fully investigating the interactions among the hormones and body composition measures; future work with larger sample sizes should investigate these interactions to understand the relationships between these measures and cognitive functioning.

In summary, our exploratory analysis adds to an emerging understanding of the relationship between obesity and cognitive function, and suggests that BMI, body composition and possibly abnormalities in glucose and/or insulin homeostasis may contribute to decreased cognitive function, even in young, otherwise healthy, women. Further research is required to isolate the effects of individual hormones in the obesity milieu, from obesity itself. Additionally, longitudinal prospective studies are required to determine causality.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the study participants for their participation in the study and the Clinical Research Staff for their contributions.

This research was supported by R01 HL-077674, K23 RR-23090 and UL1 RR-025758.

References

- Hedley AA, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA: the journal of the American Medical Association. 2004; 291:2847– 2850.10.1001/jama.291.23.2847 [PubMed: 15199035]
- Schuur M, et al. Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. European journal of epidemiology. 2010; 25:561– 568.10.1007/s10654-010-9476-y [PubMed: 20585974]
- 3. Segura B, et al. Mental slowness and executive dysfunctions in patients with metabolic syndrome. Neuroscience letters. 2009; 462:49–53.10.1016/j.neulet.2009.06.071 [PubMed: 19560512]
- Hassenstab JJ, Sweat V, Bruehl H, Convit A. Metabolic syndrome is associated with learning and recall impairment in middle age. Dementia and geriatric cognitive disorders. 2010; 29:356– 362.10.1159/000296071 [PubMed: 20424454]
- Gunstad J, Lhotsky A, Wendell CR, Ferrucci L, Zonderman AB. Longitudinal examination of obesity and cognitive function: results from the Baltimore longitudinal study of aging. Neuroepidemiology. 2010; 34:222–229.10.1159/000297742 [PubMed: 20299802]
- Gustafson D, Lissner L, Bengtsson C, Bjorkelund C, Skoog I. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2004; 63:1876–1881. [PubMed: 15557505]
- Brooks SJ, et al. Late-life obesity is associated with smaller global and regional gray matter volumes: a voxel-based morphometric study. International journal of obesity. 201210.1038/ijo. 2012.13
- Gunstad J, et al. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Comprehensive psychiatry. 2007; 48:57–61.10.1016/j.comppsych.2006.05.001 [PubMed: 17145283]
- Boeka AG, Lokken KL. Neuropsychological performance of a clinical sample of extremely obese individuals. Archives of clinical neuropsychology: the official journal of the National Academy of Neuropsychologists. 2008; 23:467–474.10.1016/j.acn.2008.03.003 [PubMed: 18448310]
- Fergenbaum JH, et al. Obesity and lowered cognitive performance in a Canadian First Nations population. Obesity. 2009; 17:1957–1963.10.1038/oby.2009.161 [PubMed: 19478788]

Bove et al.

- 11. Etou H, et al. Characteristics of psychomotor performance and time cognition in moderately obese patients. Physiology & behavior. 1989; 45:985–988. [PubMed: 2780884]
- Lokken KL, Boeka AG, Yellumahanthi K, Wesley M, Clements RH. Cognitive performance of morbidly obese patients seeking bariatric surgery. The American surgeon. 2010; 76:55–59. [PubMed: 20135940]
- Nilsson LG, Nilsson E. Overweight and cognition. Scandinavian journal of psychology. 2009; 50:660–667.10.1111/j.1467-9450.2009.00777.x [PubMed: 19930267]
- Lokken KL, Boeka AG, Austin HM, Gunstad J, Harmon CM. Evidence of executive dysfunction in extremely obese adolescents: a pilot study. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery. 2009; 5:547–552.10.1016/j.soard. 2009.05.008 [PubMed: 19766958]
- Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabetic medicine: a journal of the British Diabetic Association. 201110.1111/j.1464-5491.2011.03464.x
- Crichton GE, et al. Metabolic Syndrome, Cognitive Performance, and Dementia. Journal of Alzheimer's disease: JAD. 201110.3233/JAD-2011-111022
- Benedict C, et al. Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly. Diabetes care. 2012; 35:488–494.10.2337/dc11-2075 [PubMed: 22301128]
- Gonzales MM, et al. Insulin sensitivity as a mediator of the relationship between BMI and working memory-related brain activation. Obesity. 2010; 18:2131–2137.10.1038/oby.2010.183 [PubMed: 20814415]
- Krug R, Benedict C, Born J, Hallschmid M. Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. The Journal of clinical endocrinology and metabolism. 2010; 95:E468–472.10.1210/jc.2010-0744 [PubMed: 20719831]
- Gunnell D, Miller LL, Rogers I, Holly JM. Association of insulin-like growth factor I and insulinlike growth factor-binding protein-3 with intelligence quotient among 8- to 9-year-old children in the Avon Longitudinal Study of Parents and Children. Pediatrics. 2005; 116:e681–686.10.1542/ peds.2004-2390 [PubMed: 16263982]
- Okereke O, et al. Plasma IGF-I levels and cognitive performance in older women. Neurobiology of aging. 2007; 28:135–142.10.1016/j.neurobiolaging.2005.10.012 [PubMed: 16337715]
- Arwert LI, Deijen JB, Drent ML. The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society. 2005; 15:416– 422.10.1016/j.ghir.2005.09.001 [PubMed: 16256385]
- Aleman A, Torres-Aleman I. Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Progress in neurobiology. 2009; 89:256–265.10.1016/ j.pneurobio.2009.07.008 [PubMed: 19665513]
- Kamogawa K, et al. Abdominal fat, adipose-derived hormones and mild cognitive impairment: the J-SHIPP study. Dementia and geriatric cognitive disorders. 2010; 30:432–439.10.1159/000321985 [PubMed: 21088422]
- 25. Gunstad J, et al. Serum leptin levels are associated with cognitive function in older adults. Brain research. 2008; 1230:233–236.10.1016/j.brainres.2008.07.045 [PubMed: 18675793]
- Dumas JA, Kutz AM, Naylor MR, Johnson JV, Newhouse PA. Increased memory load-related frontal activation after estradiol treatment in postmenopausal women. Hormones and behavior. 2010; 58:929–935.10.1016/j.yhbeh.2010.09.003 [PubMed: 20849856]
- 27. Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: A review. Maturitas. 2011; 69:322–337.10.1016/j.maturitas.2011.05.012 [PubMed: 21696899]
- Young LA, Neiss MB, Samuels MH, Roselli CE, Janowsky JS. Cognition is not modified by large but temporary changes in sex hormones in men. The Journal of clinical endocrinology and metabolism. 2010; 95:280–288.10.1210/jc.2009-1346 [PubMed: 19880786]
- Annweiler C, et al. Dietary intake of vitamin D and cognition in older women: a large populationbased study. Neurology. 2010; 75:1810–1816.10.1212/WNL.0b013e3181fd6352 [PubMed: 21079183]

Bove et al.

- 30. Bredella MA, et al. Effects of growth hormone in women with abdominal obesity: a 6-month randomized, double-blind, placebo-controlled trial. Eur J Endocrinol. 201210.1530/EJE-11-1068
- 31. Strauss, E.; Sherman, EMS.; Spreen, O. A Compendium of Neuropsychological Tests: Administration, Norms and Commentary. 3. Oxford University Press; 2006.
- Miller KK, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. The Journal of clinical endocrinology and metabolism. 2004; 89:525–533. [PubMed: 14764757]
- Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. Brain and cognition. 1990; 14:26–43. [PubMed: 2223043]
- 34. Cereda E, Sansone V, Meola G, Malavazos AE. Increased visceral adipose tissue rather than BMI as a risk factor for dementia. Age and ageing. 2007; 36:488–491.10.1093/ageing/afm096 [PubMed: 17656423]
- Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Archives of neurology. 2010; 67:428– 433.10.1001/archneurol.2010.38 [PubMed: 20385908]
- 36. Porter DW, Irwin N, Flatt PR, Holscher C, Gault VA. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. European journal of pharmacology. 2011; 650:688–693.10.1016/j.ejphar.2010.10.059 [PubMed: 21050845]
- 37. Frisardi V, et al. Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? Journal of Alzheimer's disease: JAD. 2010; 21:57–63.10.3233/JAD-2010-100015
- 38. Sakata A, et al. Female exhibited severe cognitive impairment in type 2 diabetes mellitus mice. Life sciences. 2010; 86:638–645.10.1016/j.lfs.2010.03.003 [PubMed: 20226793]
- Holden KF, et al. Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiology of aging. 2009; 30:1483–1489.10.1016/j.neurobiolaging.2007.11.024 [PubMed: 18358569]
- 40. Tolppanen AM, Williams DM, Lawlor DA. The association of serum ionized calcium and vitamin D with adult cognitive performance. Epidemiology. 2011; 22:113–117.10.1097/EDE. 0b013e3181f74683 [PubMed: 20881598]

Bove et al.




Figure 1.

Plots of mean z-scores for verbal learning and memory domain, adjusted for age and education, by body composition parameters.

Models for subcutaneous (SAT) and total (TAT) abdominal fat yielded significant associations with verbal learning and memory (p=0.010 and p=0.019 respectively, but not for BMI or muscle (p=0.087 and p=0.114, respectively). For SAT and TAT, group differences significant by student's t test to p<0.05 are indicated with a *.

A. Subjects were divided by BMI, into normal (18<BMI<25 kg/m², N=12), overweight by WHO criteria (25 BMI<30 kg/m², N=8) and obese by WHO criteria (BMI 30kg/m², N=29).

B. Subjects were divided by subcutaneous abdominal fat, with 1st tertile ranging from 7250 to 29570 mm² (N=16), 2nd tertile ranging from 32430 to 47680 mm² (N=16), and 3rd tertile ranging from 47850 to 80010 mm² (N=16).

C. Subjects were divided by total abdominal fat, with 1st tertile ranging from 10360 to 40220 mm² (N=16), 2nd tertile ranging from 40750 to 59840 mm² (N=16), and 3rd tertile ranging from 60640 to 97300 mm² (N=16).

D. Subjects were divided by muscle cross-sectional area, with 1st tertile ranging from 7578 to 12276 mm² (N=16), 2nd tertile ranging from 12312 to 14539 mm² (N=16), and 3rd tertile ranging from 14743 to 18663 mm² (N=16).




Figure 2.

Partial regression plot for executive function domain z score by HOMA-IR, adjusted for age and education. Partial r = -0.34, p = 0.021.

NIH-PA Author Manuscript

acteristics.
chara
Subject

49 years) $34.6 (35; 22-45; 7.0)$ years) $34.6 (35; 22-45; 7.0)$ years) $31.5 (32.5; 18.1-47.5; 7.4)$ ation (years) $16.1 (16; 12-24; 2.1)$ ket 78% ation American 4% ation American 4% ation (years) $113 (114; 87-127; 9)$ ation Scale (BD1) 90% ation Sca)	NOFILIAI- WEIGHT
34.6 (35; 22-45; 7.0) 31.5 (32; 18.1-47.5; 7.4) 31.5 (32:5; 18.1-47.5; 7.4) 16.1 (16; 12-24; 2.1) merican 16.1 (16; 12-24; 2.1) 78% merican 14% p0% p13 (14; 87-127; 9) p13 (114; 87-127; 9) p13 (114; 87-127; 9) p38% p4% p4% p4% p4% p5% p5% p13 (114; 87-127; 9) p3% p4% p4% p5% p60% p13 (114; 87-127; 9) p3% p4% p5% p4% p5% p5% p6% p60% p13 (114; 87-127; 9) p3% p4% p4% p4% p4% p4% p5% al (mcg/mL) s1.7 (26.0; 2.1-9; 2.25.7) 31.7 (26.0; 2.2-120.3; 25.7)	37	12
34.6 (35; 22-45; 7.0) 31.5 (32.5; 18.1-47.5; 7.4) 16.1 (16; 12-24; 2.1) 16.1 (16; 12-24; 2.1) nerican 14% aphi 14% aphi 14% aphi 14% asis 14% and (14; 87-127; 9) BDJ) 90% p=100, sd=15) 113 (114; 87-127; 9) BDJ) 98% p=100, sd=15) 113 (114; 87-127; 9) BDJ) 98% p=100, sd=15) 113 (114; 87-127; 9) attractan 4% AUC 113 (114; 87-127; 9) attractan 2% AUC 113 (114; 87-127; 9) attractan 113 (114; 87-127; 9) attractan 2% AUC 14932 (14580; 10530-24720; 3242) attractan 5.65 (6.0; 2.1-9.5; 1.96) attractan 5.65 (6.0; 2.1-9.5; 1263) attractan 5.65 (6.0; 2.2-120.3; 25.7)	Mean (median; range; standard deviation)	
31.5 (32.5; 18.1-47.5; 7.4) 16.1 (16; 12-24; 2.1) Interican American ptb 16.1 (16; 12-24; 2.1) 78% Terican 14% P300, sd=15 BD1) 90% µ=100, sd=15 11.3 (114; 87-127; 9) BD1) 98% 2% AUC 14932 (14580; 10530-24720; 3242) alt (mcg/mL) 5.65 (60; 2.1-9.5; 1.96) 31.7 (26.0; 2.2-120.3; 25.7)	35.5 (37; 22–45; 7.1)	31.6 (30; 22–45; 6.4)
I6.1 (16; 12-24; 2.1) I6.1 (16; 12-24; 2.1) American 14% artican 4% ght) 14% ght) 14% 90% 4% 90% 113 (114; 87-127; 9) 90% 9113 (114; 87-127; 9) 911 913 (114; 87-127; 9) 914 913 (114; 87-127; 9) 913 (114; 87-127; 9) 913 (114; 87-127; 9) 913 (114; 87-127; 9) 913 (114; 87-127; 9) 913 (1180; 0.082-4.317; 0.994) al (mcg/mL) 5.65 (6.0; 2.1-9.5; 1.96) 31.7 (26.0; 2.2-120.3; 25.7)	34.7 (34.7; 25.1–47.5; 5.5)	21.9 (22.3; 18.1–24.6; 2.2)
ite 78% ck/African American 14% an/Asian American 14% an/Asian American 4% er 4% er 90% choses (% Right) 113 (114; 87–127; 9) std score (µ=100, sd=15) 913 (114; 87–127; 9) ssion Scale (BDI) 98% d 2% d 2% MONES 113 (114; 87–127; 9) winal 98% d 2% d 2% MONES 14932 (14580; 10530–24720; 3242) MONES 14932 (14580; 10530–24720; 3242) MONES 4922 (3344; 179–13152; 3455) MA-IR 14932 (14580; 10530–24720; 3242) MA-IR 14932 (14580; 10530–24720; 3242) Monectin, total (mcg/mL) 31.7 (26.0; 2.1–9.5; 1.96) fin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)	15.9 (16; 12–24; 2.3)	16.6 (16.5; 14–19; 1.3)
nite 78% kek/African American 14% kek/African American 4% ian/Asian American 4% ner 4% ner 4% edness (% Right) 90% edness (% Right) 90% std score (µ=100, sd=15) 90% ssion Scale (BDI) 98% nimal 98% dd 2% MONES 113 (114; 87–127; 9) sesion Scale (BDI) 98% nimal 2% dd 2% MONES 113 (114; 87–127; 9) see Homeostasis 143 (114; 87–127; 9) bin AUC 4922 (14580; 10530–24720; 3242) MONES 4922 (14580; 10530–24720; 3242) MA-IR 14932 (14580; 10530–24720; 3242) binectin, total (mcg/mL) 5.65 (6.0; 2.1–9.5; 1.96)		
kck/African American 14% ian/Asian American 4% ner 4% ner 90% edness (% Right) 90% R std score (µ=100, sd=15) 9113 (114; 87–127; 9) ssion Scale (BD1) 98% nimal 98% dd 2% MONES 113 (114; 87–127; 9) sestion Scale (BD1) 98% nimal 98% dd 2% MONES 98% MONES 98% MONES 14932 (14580; 10530–24720; 3242) ulin AUC 14932 (14580; 10530–24720; 3242) Julin AUC 4922 (3344; 179–13152; 3455) MA-IR 1.413 (1.180; 0.082–4.317; 0.994) Steines 5.65 (6.0; 2.1–9.5; 1.96) pitn (ng/mL) 5.65 (6.0; 2.1–9.5; 1.96)	76%	83%
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	19%	0%
ner 4% edness (% Right) 90% edness (% Right) 90% R std score (µ=100, sd=15) 913 (114; 87–127; 9) ession Scale (BDI) 98% nimal 98% ssion Scale (BDI) 98% nimal 98% nome 98% nom 98% nom 98% nom 2% MONES 2% MONES 4922 (14580; 10530–24720; 3242) see Homeostasis 14932 (14580; 10530–24720; 3242) ulin AUC 14932 (14580; 10530–24720; 3242) MA-IR 14932 (14580; 10530–24720; 3242) oster Homeostasis 14932 (14580; 10530–24720; 3245) oster Homeostasis	3%	8%
edness (% Right) 90% R std score (µ=100, sd=15) 113 (114; 87-127; 9) ession Scale (BD1) 98% nimal 98% dd 2% MONES 2% MONES 2% MONES 14932 (14580; 10530-24720; 3242) ulin AUC 4922 (3344; 179-13152; 3455) ulin AUC 4922 (14580; 10530-24720; 3242) bin AUC 14932 (14580; 10530-24720; 3242) ose Homeostasis 14932 (14580; 10530-24720; 3242) bin AUC 14932 (14580; 10530-24720; 3242) bin AUC 14932 (14580; 10530-24720; 3242) ose Homeostasis 11413 (1.180; 0.082-4.317; 0.994) bin AUC 31.7 (26.0; 2.1-9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2-120.3; 25.7)	3%	8%
R std score (µ=100, sd=15) 113 (114; 87-127; 9) ession Scale (BD1) 98% nimal 98% dd 2% MONES 2% MONES 2% MONES 14932 (14580; 10530-24720; 3242) ose Homeostasis 14932 (14580; 10530-24720; 3242) ose OCTT AUC 14932 (14580; 10530-24720; 3242) ose OCTT AUC 4922 (3344; 179-13152; 3455) other R 1.413 (1.180; 0.082-4.317; 0.994) okines 5.65 (6.0; 2.1-9.5; 1.96) opin (ng/mL) 31.7 (26.0; 2.2-120.3; 25.7)	92%	83%
ssion Scale (BD1) nimal 98% Id 2% MONES 98% MONES 14580; 10530-24720; 3242) se Homeostasis Leose OGTT AUC 14932 (14580; 10530-24720; 3242) ulin AUC 4922 (3344; 179-13152; 3455) Ulin AUC 4922 (3344; 179-13152; 3455) MA-IR 11413 (1.180; 0.082-4.317; 0.994) bin AUC 5.65 (6.0; 2.1-9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2-120.3; 25.7)	112 (114; 87–127; 9)	117 (117; 106–127; 7)
nimal 98% Id 2% MONES 2% MONES 2% MONES 14932 (14580; 10530–24720; 3242) se Homeostasis 14932 (14580; 10530–24720; 3242) Julin AUC 4922 (3344; 179–13152; 3455) MA-IR 1.413 (1.180; 0.082–4.317; 0.994) Skines 5.65 (6.0; 2.1–9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)		
Id 2% MONES 2% MONES 14932 See Homeostasis 14932 Lecose OGTT AUC 14932 Ulin AUC 4922 MA-IR 1.413 MA-IR 1.413 Sef (60; 2.1-9.5; 1.96) ptin (ng/mL) 31.7	97%	100%
MONES MONES bse Homeostasis 14932 (14580; 10530–24720; 3242) Lcose OGTT AUC 14932 (14580; 10530–24720; 3242) ulin AUC 4922 (3344; 179–13152; 3455) MA-IR 1.413 (1.180; 0.082–4.317; 0.994) okines 5.65 (6.0; 2.1–9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)	3%	0%
se Homeostasis 14932 (14580; 10530-24720; 3242) Leose OGTT AUC 14932 (14580; 10530-24720; 3242) ulin AUC 4922 (3344; 179-13152; 3455) DMA-IR 1.413 (1.180; 0.082-4.317; 0.994) Shines 5.65 (6.0; 2.1-9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2-120.3; 25.7)		
Lcose OGTT AUC 14932 (14580; 10530–24720; 3242) ulin AUC 4922 (3344; 179–13152; 3455) MA-IR 1.413 (1.180; 0.082–4.317; 0.994) Shines 5.65 (6.0; 2.1–9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)		
ulin AUC 4922 (3344; 179–13152; 3455) MA-IR 1.413 (1.180; 0.082–4.317; 0.994) okines 5.65 (6.0; 2.1–9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)	15735 (15615; 10605–24720; 3234)	12455 (12210; 10602–14970; 1665)
MA-IR 1.413 (1.180; 0.082–4.317; 0.994) okines 5.65 (6.0; 2.1–9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)	5726 (4692; 941–13152; 3515)	2219 (2256; 179–3649; 1094)
skines 5.65 (6.0; 2.1–9.5; 1.96) iponectin, total (mcg/mL) 31.7 (26.0; 2.2–120.3; 25.7)	1.626 (1.517; 0.116–4.317; 1.018)	0.69 (0.706; 0.082–1.489; 0.430)
iponectin, total (mcg/mL) 5.65 (6.0; 2.1–9.5; 1.96) ptin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)		
ptin (ng/mL) 31.7 (26.0; 2.2–120.3; 25.7)	5.3 (5.9; 2.1–8.3; 2.0)	6.3 (6.3; 3.2–9.5; 1.9)
	43.2 (40.9; 9.6–120.3; 25.7)	12.6 (9.7; 2.2–35.3; 9.1)
IGF1		
IGF-1 (ng/mL) 131 (131; 46–329; 50.1)	129 (130; 46–329; 55.2)	136 (143; 86–185; 28.8)

_
T
-
0
~
~
<u> </u>
+
utho
0
_
~
\geq
0)
<u> </u>
<u> </u>
_
<u></u>
S
nusc
_ .
4

_	
2	
=	
÷.	
÷n.	
~	
Þ	
7	
É	
÷	
ğ	
~	
<u>ש</u>	
2	
IUSCI	
S	
0	
<u>_</u>	
9	

	All Women	Overweight/Obese	Normal-Weight
Free Estradiol (pg/mL)	74.6 (57.4; 12–358; 61.4)	77.4 (57.6; 17.6–357.8; 64.8)	66.0 (50.4; 12–150; 51.6)
Total Estradiol (pg/mL)	116 (91; 6–440; 85.3)	117.8 (94; 27–440; 87.2)	82.5 (78; 6–238; 82.5)
Free Testosterone (ng/dL)	0.53 (0.41; 0.11–2.64; 0.45)	0.58(0.42; 0.11-2.64; 0.49)	0.37 (0.36 ; $0.13-0.90$; 0.23)
Total Testosterone (ng/dL)	38.0 (30; 9–121; 25.5)	39 (31; 11–121; 26.9)	35 (28; 9–79; 21.0)
Vitamin D metabolism			
25 OH-Vitamin D (ng/mL)	25.3 (24; 5–69; 12.4)	23.6 (21; 5–69; 12.6)	31.1 (31; 13–46; 10.1)

*** p < 0.0001

NIH-PA Author Manuscript

Table 2

Association between body composition markers and verbal learning and memory.

Multivariate regressions for cognitive scores by individual body composition markers, controlling for age and education (N = 48). Partial correlation coefficients and p-values are provided.

	BMI (k	BMI (kg/m²)	Total Abdominal Fat (mm^2)	ıl Fat (mm²)	Visceral Abdominal Fat (mm ²)	ominal Fat ²)	Subcutaneous Abdominal Fat (mm ²)	.bdominal Fat ¹²)	Total F:	Total Fat (g)	Muscle, Thigh (mm²)	igh (mm²)
	partial r	d	partial r	d	partial r	d	partial r	d	partial r	d	partial r	d
Verbal Learning/Memory Composite Score	-0.25 0.093	0.093	-0.28	0.055	-0.33	0.024	-0.25	0.099	-0.25	0.094	-0.38	0.012
Short Delay Free Recall	-0.22	0.139	-0.23	0.121	-0.27	0.067	-0.20	0.183	-0.19	0.204	-0.33	0.024
Short Delay Cued Recall	-0.22	0.139	-0.23	0.115	-0.25	0.097	-0.21	0.160	-0.21	0.156	-0.39	0.006
Long Delay Free Recall	-0.15	0.331	-0.19	0.204	-0.28	0.054	-0.15	0.325	-0.13	0.382	-0.25	0.105
Long Delay Cued Recall	-0.19	0.206	-0.21	0.155	-0.26	0.075	-0.18	0.231	-0.18	0.226	-0.33	0.028
Trials 1–5	-0.39 0.007	0.007	-0.39	0.007	-0.42	0.003	-0.34	0.018	-0.39	0.007	-0.53	0.000